Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm

If you purchased or acquired stock in Unicycive and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.

NEW YORK, July 02, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C ., a nationally recognized stockholder rights law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) on behalf of Unicycive stockholders. Our investigation concerns whether Unicycive has violated the federal securities laws and/or engaged in other unlawful business practices.

Investigation Details: On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) regarding the Company’s resubmitted New Drug Application for oxylanthanum carbonate for kidney disease therapy. The Company disclosed that the CRL was based on the same third-party manufacturing deficiencies identified in the prior June 2025 CRL.

On this news, the price of Unicycive shares declined by $3.01 per share, or approximately 39%, from $7.70 per share on June 29, 2026 to close at $4.69 on June 30, 2026.

Next Steps: If you purchased or otherwise acquired Unicycive shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or...